The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. [electronic resource]
Producer: 20210525Description: 3-16 p. digitalISSN:- 1468-1293
- Adenine -- adverse effects
- Alanine
- Anti-HIV Agents -- adverse effects
- CD4 Lymphocyte Count
- Comorbidity
- Drug Combinations
- Emtricitabine
- Equivalence Trials as Topic
- HIV Infections -- blood
- Heterocyclic Compounds, 4 or More Rings -- adverse effects
- Humans
- Piperazines
- Pyridones
- Risk Factors
- Socioeconomic Factors
- Tablets
- Tenofovir -- adverse effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.